An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets.
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2011
At a glance
- Drugs Fostamatinib (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T cell lymphoma
- Focus Pharmacokinetics
- 27 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 16 Aug 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.